Total for the last 12 months
number of access : ?
number of downloads : ?
ID 117802
Author
Sezai, Akira Nihon University
Tanaka, Atsushi Saga University
Imai, Takumi Osaka Metropolitan University
Kida, Keisuke St. Marianna University School of Medicine
Sekino, Hisakuni Sekino Hospital
Murohara, Toyoaki Nagoya University
Suzuki, Norio St. Marianna University School of Medicine
Node, Koichi Saga University
Keywords
sodium–glucose transporter 2 inhibitors
diabetes
heart failure
NT-proBNP
BMI
Content Type
Journal Article
Description
Background: We present results of a 24-week comparative study of the effects of the sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin vs. the sulfonylurea glimepiride, by baseline body mass index (BMI), in patients with type 2 diabetes and chronic heart failure. Methods: We conducted a post hoc analysis of the CANDLE trial. This subanalysis evaluated NT-proBNP, BMI, and other laboratory parameters, according to the subgroups stratified by BMI ≥ 25 kg/m2 vs. BMI < 25 kg/m2. Results: A group ratio of proportional changes in the geometric means of NT-proBNP was 0.99 (p = 0.940) for the subgroup with BMI ≥ 25 kg/m2 and 0.85 (p = 0.075) for the subgroup with BMI < 25 kg/m2, respectively. When baseline BMI was modeled as a continuous variable, results for patients with BMI < 30 kg/m2 showed a slightly smaller increase in NT-proBNP in the canagliflozin group vs. the glimepiride group (p = 0.295); that difference was not seen among patients with BMI ≥30 kg/m2 (p = 0.948). Irrespective of obesity, the canagliflozin group was associated with significant reduction in BMI compared to the glimepiride group. Conclusion: There was no significant difference in the effects of canagliflozin, relative to glimepiride, on NT-proBNP concentrations irrespective of baseline obesity. UMIN clinical trial registration number: UMIN000017669.
Journal Title
Biomedicines
ISSN
22279059
Publisher
MDPI
Volume
10
Issue
7
Start Page
1656
Published Date
2022-07-09
Rights
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences